This week, six Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Ariad Pharmaceuticals (NASDAQ:ARIA) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Puma Biotechnology Inc. (NYSE:PBYI) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. The stock price has risen 11.8% over the past month, better than the 5.7% increase the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of PBYI stock.
This week, Neurocrine Biosciences’ (NASDAQ:NBIX) ratings are up from a C last week to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Array BioPharma (NASDAQ:ARRY) shows solid improvement this week. The company’s rating rises from a C to a B. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
Celldex Therapeutics (NASDAQ:CLDX) gets a higher grade this week, advancing from a B last week to an A. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
Insmed Inc.’s (NASDAQ:INSM) ratings are looking better this week, moving up to a B from last week’s C. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
